726 related articles for article (PubMed ID: 30027778)
1. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
Patel PJ; Gajera BY; Dave RH
Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
[TBL] [Abstract][Full Text] [Related]
2. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
3. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
[TBL] [Abstract][Full Text] [Related]
4. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
5. Identification of critical process parameters and its interplay with nanosuspension formulation prepared by top down media milling technology--a QbD perspective.
Ghosh I; Schenck D; Bose S; Liu F; Motto M
Pharm Dev Technol; 2013; 18(3):719-29. PubMed ID: 23061898
[TBL] [Abstract][Full Text] [Related]
6. Investigation of preparation parameters of nanosuspension by top-down media milling to improve the dissolution of poorly water-soluble glyburide.
Singh SK; Srinivasan KK; Gowthamarajan K; Singare DS; Prakash D; Gaikwad NB
Eur J Pharm Biopharm; 2011 Aug; 78(3):441-6. PubMed ID: 21439378
[TBL] [Abstract][Full Text] [Related]
7. Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension.
Zhang K; Yu H; Luo Q; Yang S; Lin X; Zhang Y; Tian B; Tang X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1285-92. PubMed ID: 23562534
[TBL] [Abstract][Full Text] [Related]
8. Spray drying of drug-swellable dispersant suspensions for preparation of fast-dissolving, high drug-loaded, surfactant-free nanocomposites.
Azad M; Arteaga C; Abdelmalek B; Davé R; Bilgili E
Drug Dev Ind Pharm; 2015; 41(10):1617-31. PubMed ID: 25347144
[TBL] [Abstract][Full Text] [Related]
9. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
Nagaraj K; Narendar D; Kishan V
Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
[TBL] [Abstract][Full Text] [Related]
10. Optimization of formulation and process parameters for the production of carvedilol nanosuspension by wet media milling.
Medarević D; Djuriš J; Ibrić S; Mitrić M; Kachrimanis K
Int J Pharm; 2018 Apr; 540(1-2):150-161. PubMed ID: 29438724
[TBL] [Abstract][Full Text] [Related]
11. Identifying the correlation between drug/stabilizer properties and critical quality attributes (CQAs) of nanosuspension formulation prepared by wet media milling technology.
George M; Ghosh I
Eur J Pharm Sci; 2013 Jan; 48(1-2):142-52. PubMed ID: 23085547
[TBL] [Abstract][Full Text] [Related]
12. Universal wet-milling technique to prepare oral nanosuspension focused on discovery and preclinical animal studies - Development of particle design method.
Niwa T; Miura S; Danjo K
Int J Pharm; 2011 Feb; 405(1-2):218-27. PubMed ID: 21167922
[TBL] [Abstract][Full Text] [Related]
13. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling.
Liu P; Rong X; Laru J; van Veen B; Kiesvaara J; Hirvonen J; Laaksonen T; Peltonen L
Int J Pharm; 2011 Jun; 411(1-2):215-22. PubMed ID: 21458552
[TBL] [Abstract][Full Text] [Related]
14. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
[TBL] [Abstract][Full Text] [Related]
15. Improved oral bioavailability of core-shell structured beads by redispersion of the shell-forming nanoparticles: preparation, characterization and in vivo studies.
Yao Q; Tao X; Tian B; Tang Y; Shao Y; Kou L; Gou J; Li X; Yin T; Tang X
Colloids Surf B Biointerfaces; 2014 Jan; 113():92-100. PubMed ID: 24060933
[TBL] [Abstract][Full Text] [Related]
16. Isoliquiritigenin Nanosuspension Enhances Cytostatic Effects in A549 Lung Cancer Cells.
Qiao F; Zhao Y; Mai Y; Guo J; Dong L; Zhang W; Yang J
Planta Med; 2020 May; 86(8):538-547. PubMed ID: 32294789
[TBL] [Abstract][Full Text] [Related]
17. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation.
Patel GV; Patel VB; Pathak A; Rajput SJ
Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Process and Formulation Parameters on the Fabrication of Efavirenz Nanosuspension to Improve Drug Solubility and Dissolution.
Rashed M; Dadashzadeh S; Bolourchian N
Iran J Pharm Res; 2022 Dec; 21(1):e129409. PubMed ID: 36942076
[TBL] [Abstract][Full Text] [Related]
19. In vitro/in vivo evaluation of felodipine micropowders prepared by the wet-milling process combined with different solidification methods.
Meng J; Li S; Yao Q; Zhang L; Weng Y; Cai C; Xu H; Tang X
Drug Dev Ind Pharm; 2014 Jul; 40(7):929-36. PubMed ID: 23614872
[TBL] [Abstract][Full Text] [Related]
20. Investigation of Formulation and Process Parameters of Wet Media Milling to Develop Etodolac Nanosuspensions.
Karakucuk A; Celebi N
Pharm Res; 2020 May; 37(6):111. PubMed ID: 32476048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
